Dr Lal PathLabs reports Q3 revenue of Rs 660 crore, posts strong growth amid labour code impact
The company recorded consolidated revenue of Rs. 660 crore in Q3 FY26, up
The company recorded consolidated revenue of Rs. 660 crore in Q3 FY26, up
Priced at just Rs. 499 for 1-year supply, this initiative is aligned with the vision of Health for All
The company reported Q3 total income of Rs. 1,005 million, marking a 10.2% increase year-on-year
The approval follows robust data from the SWIFT and ANCHOR Phase III trials
The drug had previously received orphan drug designation for this rare cancer on March 31, 2025
Finerenone is the first therapy targeting the mineralocorticoid receptor pathway to demonstrate cardiovascular benefits in heart failure patients
Moraine will serve as OTSAW’s exclusive distributor in Japan, deploying the Camello+ autonomous mobile robot and TransCar autonomous guided vehicle to support hospital logistics
Transformation to increase speed and redirect resources to growth opportunities within diabetes and obesity, aiming at reaching millions of untreated patients
Subscribe To Our Newsletter & Stay Updated